Literature DB >> 20057308

Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration.

Sarah E Hudelson1, Michelle S McConnell, Danstan Bagenda, Estelle Piwowar-Manning, Teresa L Parsons, Monica L Nolan, Paul M Bakaki, Michael C Thigpen, Michael Mubiru, Mary Glenn Fowler, Susan H Eshleman.   

Abstract

OBJECTIVE: Single-dose nevirapine (NVP) (sdNVP) can reduce the risk of HIV vertical transmission. We assessed risk factors for NVP resistance in plasma and breast milk from sdNVP-exposed Ugandan women.
METHODS: Samples were analyzed using the Roche AMPLICOR HIV-1 Monitor Test Kit, version 1.5, and the ViroSeq HIV-1 Genotyping System. NVP concentrations were determined by liquid chromatography with tandem mass spectroscopy.
RESULTS: HIV genotypes (plasma and breast milk) were obtained for 30 women 4 weeks after sdNVP (HIV subtypes: 15A, 1C, 12D, two recombinant). NVP resistance was detected in 12 (40%) of 30 breast milk samples. There was a nonsignificant trend between detection of NVP resistance in breast milk and plasma (P = 0.06). There was no association of HIV resistance in breast milk with median maternal pre-NVP viral load or CD4 cell count, median breast milk viral load at 4 weeks, breast milk sodium more than 10 mmol/l, HIV subtype, or concentration of NVP in breast milk or plasma.
CONCLUSION: NVP resistance was frequently detected in breast milk 4 weeks after sdNVP exposure. In this study, we were unable to identify specific factors associated with breast milk NVP resistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20057308      PMCID: PMC3065236          DOI: 10.1097/QAD.0b013e3283346e60

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  15 in total

1.  Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012).

Authors:  Susan H Eshleman; Laura A Guay; Anthony Mwatha; Elizabeth R Brown; Shawn P Cunningham; Philippa Musoke; Francis Mmiro; J Brooks Jackson
Journal:  J Acquir Immune Defic Syndr       Date:  2004-02-01       Impact factor: 3.731

2.  Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia.

Authors:  Nicola Mackie; Simon Dustan; Myra O McClure; Jonathan N Weber; John R Clarke
Journal:  J Virol Methods       Date:  2004-08       Impact factor: 2.014

3.  Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies.

Authors:  Eva Muro; Jacqueline A H Droste; Hadewych Ter Hofstede; Marjolein Bosch; Wil Dolmans; David M Burger
Journal:  J Acquir Immune Defic Syndr       Date:  2005-08-01       Impact factor: 3.731

4.  Rapid and simple method for purification of nucleic acids.

Authors:  R Boom; C J Sol; M M Salimans; C L Jansen; P M Wertheim-van Dillen; J van der Noordaa
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

5.  Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine.

Authors:  Esther J Lee; Rami Kantor; Lynn Zijenah; Wayne Sheldon; Lynda Emel; Patrick Mateta; Elizabeth Johnston; Jennifer Wells; Avinash K Shetty; Hoosen Coovadia; Yvonne Maldonado; Samuel Adeniyi Jones; Lynne M Mofenson; Christopher H Contag; Mary Bassett; David A Katzenstein
Journal:  J Infect Dis       Date:  2005-08-23       Impact factor: 5.226

6.  A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).

Authors:  P Musoke; L A Guay; D Bagenda; M Mirochnick; C Nakabiito; T Fleming; T Elliott; S Horton; K Dransfield; J W Pav; A Murarka; M Allen; M G Fowler; L Mofenson; D Hom; F Mmiro; J B Jackson
Journal:  AIDS       Date:  1999-03-11       Impact factor: 4.177

7.  Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.

Authors:  Susan H Eshleman; Donald R Hoover; Shu Chen; Sarah E Hudelson; Laura A Guay; Anthony Mwatha; Susan A Fiscus; Francis Mmiro; Philippa Musoke; J Brooks Jackson; Newton Kumwenda; Taha Taha
Journal:  J Infect Dis       Date:  2005-06-01       Impact factor: 5.226

8.  Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

Authors:  S H Eshleman; M Mracna; L A Guay; M Deseyve; S Cunningham; M Mirochnick; P Musoke; T Fleming; M Glenn Fowler; L M Mofenson; F Mmiro; J B Jackson
Journal:  AIDS       Date:  2001-10-19       Impact factor: 4.177

9.  Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis.

Authors:  Seble Kassaye; Esther Lee; Rami Kantor; Elizabeth Johnston; Mark Winters; Lynn Zijenah; Patrick Mateta; David Katzenstein
Journal:  AIDS Res Hum Retroviruses       Date:  2007-08       Impact factor: 2.205

10.  Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration.

Authors:  Andrea Kunz; Monika Frank; Kizito Mugenyi; Rose Kabasinguzi; Astrid Weidenhammer; Michael Kurowski; Charlotte Kloft; Gundel Harms
Journal:  J Antimicrob Chemother       Date:  2008-10-30       Impact factor: 5.790

View more
  4 in total

Review 1.  Human Milk Microbiota: Transferring the Antibiotic Resistome to Infants.

Authors:  Lahari Das; Richa Virmani; Vishal Sharma; Deepti Rawat; Yogendra Singh
Journal:  Indian J Microbiol       Date:  2019-09-05       Impact factor: 2.461

2.  Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.

Authors:  Deborah Persaud; Abubaker Bedri; Carrie Ziemniak; Anitha Moorthy; Berhanu Gudetta; Aida Abashawl; Yohannes Mengistu; Saad B Omer; Abdulhamid Isehak; Solomon Kumbi; Rahel Adamu; Sileshi Lulseged; Roxann Ashworth; Elham Hassen; Andrea Ruff
Journal:  AIDS Res Hum Retroviruses       Date:  2011-02-25       Impact factor: 2.205

3.  Nevirapine-Resistant HIV-1 DNA in Breast Milk After Single-Dose Nevirapine With or Without Zidovudine for Prevention of Mother-to-Child Transmission.

Authors:  Soren Gantt; Rachel Payant; Jacquelyn Carlsson; Mark A Micek; Ana Judith Blanco; Ingrid A Beck; Laurinda Matunha; Pablo Montoya; Eduardo Matediana; Stephen Gloyd; Lisa M Frenkel
Journal:  J Pediatric Infect Dis Soc       Date:  2012-07-03       Impact factor: 3.164

Review 4.  Antiretroviral bioanalysis methods of tissues and body biofluids.

Authors:  Robin DiFrancesco; Getrude Maduke; Rutva Patel; Charlene R Taylor; Gene D Morse
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.